Medarex Inc.

University of Massachusetts

Bristol-myers Squibb Compnay

Innate Pharma

E. R. Squibb Sons, Inc.

Celldex Therapeutics Limited

Mederex, Inc.

Mederax, Inc.

Robert F Graziano

Yashwant M Deo

Tibor P Keler

Joel Goldstein

Gregory Babcock

Israel Lowy

William D Thomas, Jr

Teresa J Broering

Robert Barry Mandell

Donna Ambrosino

Hector Javier Hernandez

Deborah Molrine

Hui-Fen Zhang

Chezian Somasundaram

Alan J Korman

Ashok Kumar Gupta

Jon Marc Wigginton

Pascale Andre

John Treml

Su Young Kim

Thomas Andrew Davis

Haichun Huang

Mohan Srinivasan

Guodong Chen

Richard Y Huang

Pavel Strop

Michelle Renee Kuhne

Karuna Sundarapandiyan

Natalie Bezman

Yiming Yin

Peter Sung Keun Lee

Gamze Ozlem Camdere

Gregory J Babcock

William D Thomas

Thomas Davis

Robert Mandell

William Thomas

Theresa Broering

The disclosure provides antibodies that specifically bind human MICA/B and methods of use thereof. In some aspects, the disclosure is directed to methods of treating a cancer in a subject, comprising administering to the subject an anti-MICA/B antibody.

Antibodies against MICA and/or MICB and uses thereof

Provided are methods for clinical treatment of cancer (e.g., solid tumors or hematological malignancies) using an anti-KIR antibody in combination with an anti-CTLA-4 antibody.

Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer

Antibodies that specifically bind to toxins of, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.

Antibodies against clostridium difficile toxins and uses thereof

[object Object]

The present invention provides method of treatment using human sequence antibodies against human CTLA-4 linked to a cytotoxic agent. In particular, methods of treating cancer and autoimmune disease are provided.

Methods of treatment using CTLA-4 antibodies

Isolated human monoclonal antibodies which bind to CD30 (e.g., human CD30) are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Human monoclonal antibodies against CD30

The present invention provides method of treatment using human sequence antibodies against human CTLA-4. In particular, methods of treating cancer are provided.

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to CD64 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating autoimmune disorders, transplant rejection, Graft Versus Host Disease, or cancer and for enhanced presentation of antigen using conjugates of an antigen and an anti-CD64 antibody.

Human monoclonal antibodies to Fc gamma receptor I (CD64)

Cells transformed to express on their surface a component which binds to an Fc receptor of an effector cell are disclosed. Also disclosed are expression vectors used to transform the cells. Once transformed, the cells bind to effector cells via the Fc receptor of the effector cell to stimulate an effector cell mediated immune response.

Cells expressing anti-Fc receptor binding components

Growing community of inventors

Frenchtown, NJ, United States of America

Robert F Graziano